« Return to News | Technology Solutions

Retroscreen Virology purchases ALPHADAS

Wednesday, July 31, 2013 11:43 AM

Retroscreen Virology Group, a virology healthcare company, has purchased the ALPHADAS clinical trials software suite to accelerate and reduce the cost of bringing anti-viral drugs, diagnostics and vaccines to market.

ALPHADAS is an eSource clinical research and early phase trials system that is mobile, schedule-driven and provides real-time bedside or station-based direct data capture that eliminates paper-based data.

ALPHADAS will increase efficiencies and quality through direct data captured from Retroscreen instrumentation and manage and monitor samples through the study lifecycle while offering real-time data review.

Retroscreen conducts the Human Viral Challenge Model in a controlled quarantine environment, providing a cost-effective study design which accelerates the selection of a safe and effective dose, and dosing regimen, for a new antiviral drug or vaccine. ALPHADAS will streamline clinical trial research processes across multiple sites.

It also will be used for accelerated recruitment, staff resourcing and site management operations.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.